The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adverse event (AE) incidence rates with cobimetinib (C) plus vemurafenib (V) treatment: Extended follow-up (f/u) of the phase III coBRIM study.
 
Brigitte Dréno
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
 
Grant A. McArthur
Consulting or Advisory Role - Provectus
Research Funding - Celgene; Pfizer; Ventana Medical Systems
Travel, Accommodations, Expenses - Novartis; Roche
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Merck
 
Susan Eng
Employment - Genentech
Stock and Other Ownership Interests - InterMune; Roche
 
Jessie J. Hsu
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Isabelle Anne Rooney
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
James M. G. Larkin
Research Funding - Novartis (Inst); Pfizer (Inst)